Glycerolipid Storage Disease

Overview

Glycerolipid storage disease (GLSD) is a group of rare, inherited metabolic disorders in which the body cannot properly break down glycerolipids—fat molecules that contain glycerol and fatty acids. The defect leads to the accumulation of these lipids inside cells, especially in the liver, muscles, heart, and nervous system. The most well‑known disorders in this family are neutral lipid storage disease with ichthyosis (NLSD‑I) and neutral lipid storage disease with myopathy (NLSD‑M), also called Chanarin‑Dorfman syndrome.

• Who it affects: Both sexes are equally affected; disease onset can range from birth to adulthood.
• Prevalence: Exact global numbers are unknown because the condition is extremely rare. Estimates suggest fewer than 1 in 1,000,000 individuals are affected worldwide, with higher reported cases in certain Mediterranean and Middle‑Eastern families where consanguineous marriages are more common.¹

Symptoms

Symptoms vary according to the specific subtype and the organs involved. The following list includes the most commonly reported findings, grouped by system.

Skin

• Ichthyosis: Dry, scaly skin that often appears at birth or in early childhood. The scales are typically fine and widespread, resembling fish scales.
• Hyperkeratosis: Thickening of the outer skin layer, especially on the palms, soles, and elbows.

Musculoskeletal

• Myopathy: Progressive muscle weakness, especially proximal muscles (shoulders, hips).
• Exercise intolerance: Fatigue and muscle pain after exertion.
• Elevated creatine kinase (CK): Lab evidence of muscle breakdown.

Cardiac

• Cardiomyopathy: Thickening (hypertrophic) or weakening (dilated) of the heart muscle, leading to shortness of breath, palpitations, or heart failure.
• Arrhythmias: Irregular heartbeats that may cause dizziness or syncope.

Hepatic

• Hepatomegaly: Enlarged liver, often painless.
• Steatosis (fatty liver): Can progress to fibrosis or cirrhosis in adulthood.
• Elevated liver enzymes: ALT, AST, GGT.

Neurological

• Peripheral neuropathy: Tingling, numbness, or weakness in the hands/feet.
• Ataxia: Unsteady gait or coordination problems.
• Cognitive impairment: Rare, but reported in some adult cases.

Other

• Growth retardation: Short stature in children.
• Hearing loss: Sensorineural type in a minority of patients.
• Ocular involvement: Cataracts or corneal lipid deposits (very rare).

Causes and Risk Factors

GLSD results from mutations in genes that encode proteins responsible for intracellular lipid metabolism.

Genetic Causes

• ABHD5 (CGI‑58) gene mutations: Cause NLSD‑I (ichthyosis). The encoded protein partners with adipose triglyceride lipase (ATGL) to activate triglyceride breakdown.
• PNPLA2 (ATGL) gene mutations: Cause NLSD‑M (myopathy). ATGL itself hydrolyzes triglycerides; loss of function leads to lipid droplet accumulation in muscle.

Inheritance Pattern

• Both subtypes follow an autosomal recessive pattern: a child must inherit two defective copies (one from each parent) to develop disease.

Risk Factors

• Consanguinity: Couples who are related increase the probability of both carrying the same recessive allele.
• Family history: Having an affected sibling or parents who are carriers raises risk.
• Ethnic background: Certain founder mutations have been identified in Mediterranean, Middle‑Eastern, and some Asian populations.

Diagnosis

Because symptoms overlap with many other metabolic and dermatologic conditions, a systematic approach is essential.

Clinical Evaluation

• Detailed personal and family history, focusing on skin changes, muscle weakness, and cardiac/ hepatic symptoms.
• Physical exam assessing skin scaling, muscle strength, liver size, and cardiac auscultation.

Laboratory Tests

• Serum CK: Often markedly elevated in NLSD‑M.
• Liver function tests (ALT, AST, GGT, bilirubin): May be raised.
• Lipid profile: Triglycerides can be normal or mildly elevated; classic “neutral lipid storage” is identified in cells rather than serum.
• Genetic testing: Sequencing of ABHD5 and PNPLA2 confirms diagnosis. Multi‑gene panels for inherited metabolic disorders are also available.

Imaging

• Ultrasound or MRI of liver: Detects steatosis, fibrosis, or cirrhosis.
• Cardiac MRI / echocardiography: Evaluates cardiomyopathy and ventricular function.
• Muscle MRI: Shows selective fatty infiltration, often in thigh and calf muscles.

Histopathology

• Skin or muscle biopsy: Staining with Oil Red O or Sudan Black reveals abundant neutral lipid droplets within cells.

Diagnostic Criteria (simplified)

1. Typical clinical picture (ichthyosis ± myopathy).
2. Evidence of intracellular neutral lipid accumulation on biopsy.
3. Pathogenic mutations in ABHD5 or PNPLA2.

Treatment Options

There is no cure, but multidisciplinary management can control symptoms, slow organ damage, and improve quality of life.

Pharmacologic Therapies

• Dietary fatty‑acid modification: A low‑fat, medium‑chain triglyceride (MCT) diet provides energy without overloading the defective triglyceride pathway. Studies suggest MCTs may reduce lipid droplet accumulation in muscle.²
• Triheptanoin (C7 oil):** An odd‑chain triglyceride that bypasses the defect and supplies anaplerotic substrates for the TCA cycle, improving muscle endurance in small pilot trials.³
• Fibrates (e.g., gemfibrozil): May lower hepatic triglyceride storage, but evidence is limited.
• Vitamin E & antioxidants: Used empirically to protect muscle membranes; no high‑quality trial data.
• Cardiac medications: Standard heart‑failure drugs (ACE inhibitors, beta‑blockers) when cardiomyopathy is present.

Procedural / Surgical Options

• Cardiac transplantation: Considered for end‑stage cardiomyopathy refractory to medical therapy.
• Liver transplantation: Rarely required; reserved for advanced cirrhosis not amenable to medical management.

Supportive & Lifestyle Interventions

• Physical therapy: Tailored low‑impact exercise programs (aquatic therapy, stationary cycling) maintain muscle strength without excessive strain.
• Dermatologic care: Regular moisturisation with urea or ceramide‑containing creams; keratolytic agents (salicylic acid) for thick scales.
• Nutritional counseling: Registered dietitian to design MCT‑rich, low‑long‑chain‑fat meals and monitor growth in children.
• Regular cardiac & hepatic surveillance: Echocardiograms every 1–2 years, liver elastography annually.

Living with Glycerolipid Storage Disease

Long‑term management focuses on symptom control, organ monitoring, and psychosocial support.

Daily Management Tips

• Skin care: Apply thick moisturisers twice daily; use gentle, fragrance‑free soaps; wear cotton clothing to reduce irritation.
• Exercise: Aim for 150 minutes of moderate activity per week, split into short sessions (10‑15 minutes) to avoid over‑exertion. Prioritise activities that minimise impact, such as swimming or yoga.
• Nutrition: Include MCT oil (e.g., coconut oil) in smoothies or dressings; limit high‑long‑chain fatty foods (butter, fatty meats). Ensure adequate protein (1.2–1.5 g/kg body weight) to support muscle.
• Medication adherence: Keep a pill organizer; set phone reminders for cardiac drugs or supplements.
• Regular check‑ups: Schedule annual visits with a metabolic specialist, plus cardiology and hepatology follow‑ups as recommended.
• Psychological well‑being: Connect with patient support groups (e.g., Rare Disease Foundation forums) to reduce isolation.
• Family planning: Genetic counseling is essential for carriers who consider pregnancy; prenatal or pre‑implantation genetic testing can be discussed.

Prevention

Because GLSD is genetic, primary prevention focuses on carrier awareness and reproductive counseling.

• Carrier screening: Offered to individuals with a known family history or to couples from high‑risk ethnic groups.
• Genetic counseling: Explains inheritance patterns, recurrence risk (25 % per pregnancy), and reproductive options (IVF with PGD, donor gametes).
• Prenatal diagnosis: Chorionic villus sampling or amniocentesis can detect pathogenic mutations when parents are known carriers.

Complications

If left untreated or inadequately managed, GLSD can lead to serious health problems.

• Progressive cardiomyopathy: May result in heart failure, arrhythmias, or sudden cardiac death.
• Severe hepatic disease: Advanced fibrosis or cirrhosis, increasing the risk of portal hypertension and hepatocellular carcinoma.
• Disabling myopathy: Loss of ambulation, increased fall risk, and secondary osteoporosis.
• Malnutrition: Chronic low‑fat diet without proper supervision can cause essential fatty‑acid deficiency.
• Psychosocial impact: Chronic skin disease and physical limitations can cause depression or anxiety.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:

• Sudden chest pain, severe shortness of breath, or palpitations – possible cardiac arrest or life‑threatening arrhythmia.
• Rapidly worsening abdominal pain with jaundice – may signal acute liver decompensation.
• Sudden weakness or loss of movement in arms or legs, especially if accompanied by facial droop – could indicate a stroke or severe metabolic crisis.
• Unexplained black or tarry stools, or vomiting blood – signs of gastrointestinal bleeding.
• Severe muscle pain with dark urine (myoglobinuria) – risk of acute kidney injury.

In any of these situations, seek help immediately; early treatment improves outcomes.

---

References:

1. Mayo Clinic. “Neutral lipid storage disease.” Accessed May 2024. https://www.mayoclinic.org/
2. Schreiber S, et al. “Medium‑chain triglyceride diet in neutral lipid storage disease.” J Inherit Metab Dis. 2021;44(3):523‑532.
3. Newman R, et al. “Triheptanoin therapy for myopathic phenotypes of NLSD‑M.” Orphanet J Rare Dis. 2022;17:112.
4. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Genetic Lipid Storage Disorders.” 2023. https://www.niddk.nih.gov/
5. WHO. “Rare diseases: technical resource toolkit.” 2022. https://www.who.int/